Want to see IN:HESTERBIO full AI Analyst Report?
HESTERBIO Stock Chart & Stats
₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)
Day’s Range― - ―
52-Week Range₹1,250.95 - ₹2,347.70
Previous CloseN/A
Volume2.45K
Average Volume (3M)308.00
Market Cap
₹17.74B
Enterprise Value₹19.38B
Total Cash (Recent Filing)₹65.38M
Total Debt (Recent Filing)₹1.95B
Price to Earnings (P/E)31.4
Beta0.54
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)66.93
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthMulti-year revenue expansion with a 2026 re-acceleration (~10.8%) points to enduring demand for Hester's veterinary vaccines and animal-health offerings. Steady top-line growth supports scale benefits, predictable production planning, and the ability to fund R&D and geographic expansion over the medium term.
Profitability RecoveryA return to solid net margins (~16.7%) and better operating profit indicates the company has improved cost structure and pricing execution. Durable margin recovery enhances cash conversion potential, strengthens internal funding for growth initiatives, and reduces sensitivity to cyclical revenue swings.
Improving Cash GenerationConsistent positive free cash flow in 2024–2026, with FCF covering ~70% of net income in 2026, shows earnings are increasingly translating into usable cash. This durable cash generation supports debt reduction, reinvestment in production capacity, and more resilient funding for commercial expansion.
Bears Say
Margin And Earnings VolatilityMaterial swings in gross and net margins reduce earnings predictability and complicate multi-period planning. Persistent volatility can hinder consistent reinvestment, make budgeting for capacity or R&D riskier, and leave the company exposed to input cost, disease-cycle, or pricing pressures over the medium term.
Weak Debt Coverage By Operating CashOperating cash flow failing to reliably cover debt obligations exposes the business to refinancing and liquidity risk if profits falter. Low coverage limits flexibility for opportunistic investments, increases sensitivity to higher interest costs, and makes capital structure management more challenging over time.
Elevated Absolute Debt HistoricallyAlthough debt-to-equity has improved, the company carried elevated absolute leverage in prior years. Persistent indebtedness can constrain strategic optionality, increase fixed costs, and reduce resilience to margin or revenue shocks, limiting long-term capital allocation flexibility.
Hester Biosciences Limited News
HESTERBIO FAQ
What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2347.70 in the past 12 months.
What is Hester Biosciences Limited’s market cap?
Hester Biosciences Limited’s market cap is ₹17.74B.
When is Hester Biosciences Limited’s upcoming earnings report date?
Hester Biosciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Hester Biosciences Limited’s earnings last quarter?
Hester Biosciences Limited released its earnings results on May 15, 2026. The company reported ₹18.787 earnings per share for the quarter, beating the consensus estimate of N/A by ₹18.787.
Is Hester Biosciences Limited overvalued?
According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 0.44%. See more information on Hester Biosciences Limited dividends here
What is Hester Biosciences Limited’s EPS estimate?
Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hester Biosciences Limited have?
Hester Biosciences Limited has 8,506,865 shares outstanding.
What happened to Hester Biosciences Limited’s price movement after its last earnings report?
Hester Biosciences Limited reported an EPS of ₹18.787 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.669%.
Which hedge fund is a major shareholder of Hester Biosciences Limited?
Currently, no hedge funds are holding shares in IN:HESTERBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hester Biosciences Limited
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.
Technical Analysis
Gufic Biosciences Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
―
Unichem Laboratories Limited
―







